Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Design Therapeutics Inc DSGN

Healthcare Biotechnology
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for... see more

Current News (NDAQ:DSGN)

Design Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 26, 2025

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

GlobeNewswire November 5, 2025

Design Therapeutics Appoints Justin Gover to Board of Directors

GlobeNewswire September 10, 2025

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

GlobeNewswire August 27, 2025

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

GlobeNewswire August 7, 2025

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

GlobeNewswire June 4, 2025

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

GlobeNewswire May 28, 2025

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

GlobeNewswire May 13, 2025

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

GlobeNewswire May 7, 2025
View More News ››

Opinion & Analysis (NDAQ:DSGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DSGN)

Be the first to post on this bullboard.

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. engages in the acquisition and exploration of mineral properties in Chile and Argentina. The company ...
View More »

Podcasts